It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Down syndrome is the most frequent chromosomal abnormality among live-born infants. All Down syndrome patients have mental retardation and are prone to develop early onset Alzheimer’s disease. However, it has not yet been elucidated whether there is a correlation between the phenotype of Down syndrome and the extra chromosome 21. In this study, we continuously cultivated induced pluripotent stem cells (iPSCs) with chromosome 21 trisomy for more than 70 weeks, and serendipitously obtained revertant cells with normal chromosome 21 diploids from the trisomic cells during long-term cultivation. Repeated experiments revealed that this trisomy rescue was not due to mosaicism of chromosome 21 diploid cells and occurred at an extremely high frequency. We herewith report the spontaneous correction from chromosome 21 trisomy to disomy without genetic manipulation, chemical treatment or exposure to irradiation. The revertant diploid cells will possibly serve a reference for drug screening and a raw material of regenerative medicinal products for cell-based therapy.
Continuously cultivated iPSCs with chromosome 21 trisomy spontaneously reverted to normal diploids. This trisomy rescue occurred without genetic manipulation, chemical treatment, or exposure to irradiation. The revertant cells can serve as a reference for drug screening and as raw materials for regenerative medicine and cell-based therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 National Center for Child Health and Development, Department of Reproductive Biology, Tokyo, Japan (GRID:grid.63906.3a) (ISNI:0000 0004 0377 2305); The Jikei University School of Medicine, Department of Obstetrics and Gynecology, Tokyo, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073)
2 National Center for Child Health and Development, Department of Reproductive Biology, Tokyo, Japan (GRID:grid.63906.3a) (ISNI:0000 0004 0377 2305)
3 National Cancer Center Research Institute, Division of Carcinogenesis and Cancer Prevention, Department of Cell Culture Technology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385)
4 The Jikei University School of Medicine, Department of Obstetrics and Gynecology, Tokyo, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073)
5 National Center for Child Health and Development, Department of Maternal-Fetal, Neonatal and Reproductive Medicine, Tokyo, Japan (GRID:grid.63906.3a) (ISNI:0000 0004 0377 2305)